Livongo Health said today it will integrate continuous glucose data from Abbott‘s (NYSE:ABT) FreeStyle Libre Pro system into its Livongo for Diabetes system, touting it as the first such system to integrate data from Abbott’s FreeStyle Libre Pro.
With the integration, users of the FreeStyle Libre Pro will be able to see a visual snapshot of their glucose data as well as patterns and trends from within the data. The system will also allow users to share their Ambulatory Glucose Profiles with personal physicians to improve treatment decisions.
“Incorporating glucose data from the FreeStyle Libre Pro will enhance the Livongo member experience by providing personalized insights to influence behavior. Teaming up with Abbott supports our efforts to leverage valuable data across the healthcare ecosystem, so that our members receive the right information, tools and support when they need it most,” Livongo chief medical officer Dr. Jennifer Schneider said in a press release.
“At Abbott, we are revolutionizing glucose monitoring with technology that provides insightful, actionable information that allows people to make more informed decisions about their health. By integrating our expertise with Livongo’s approach to chronic-condition management, we are further empowering people with diabetes to live healthier lives,” Abbott diabetes care senior VP Jared Watkin said in a prepared statement.
In April, Livongo Health said that it acquired weight-management and disease-prevention program developer Retrofit for an undisclosed amount.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.